Patient Care Prostate Cancer Clinical Trials
As senior associate athletic director for health and performance at the University of Colorado Boulder, Miguel Rueda is used to overseeing the wellness of student-athletes in sports ranging from football and basketball to golf, skiing, and lacrosse.
Patient Care Prostate Cancer Clinical Trials Urology
James Bird gets emotional talking about it. How he qualified for a clinical trial that, in his view, preserved his manhood after he was diagnosed with prostate cancer in late 2022.
“The day I went in to see if I qualified, there were 10 other guys out there in the lobby who didn’t get into the trial,” he says. “I felt so sorry for them. One of the technicians who was involved with the trial told me he was getting calls from all over, from guys begging to get in. That’s how important this is.”
Community Prostate Cancer Bladder Cancer Kidney Cancer Testicular cancer
It’s one thing to develop cancer treatment guidelines in the U.S., where even the smallest health centers have access to the same basic technology for treatment and testing. But what about creating guidelines for oncologists in Sub-Saharan Africa, where access to medical resources can be limited and the disease can present differently?
Research Prostate Cancer Cancer
As growing numbers of people diagnosed with cancer receive testing to have their cancer genetically sequenced, researchers and clinicians are learning volumes more about specific mutations and genetic alterations that can occur in each type of cancer.
Prostate Cancer Magazine Urology
It was all his grandma’s doing, says University of Colorado Cancer Center member Paul Maroni, MD.
Research Prostate Cancer Cancer
Prostate cancer is the most common cancer in men and, when caught and treated early, is considered curable. But when prostate cancer becomes metastatic, meaning it spreads to distant organs, it is no longer considered curable and novel treatment strategies are needed.
Prostate cancer is the second most common and deadly cancer in the United States. The American Cancer Society estimates that 1 in 8 men will receive a prostate cancer diagnosis in their lifetime. Treatment techniques range from aggressive therapies such as radical prostatectomy or radiation therapy to targeted therapies that treat only the affected cancer cells.
The prostate-specific antigen (PSA) is a protein produced by the prostate gland. The PSA test is a blood test used to measure the amount of this protein found in the blood. Results are reported (ng/mL), which means nanograms of PSA per milliliter of blood. High levels of PSA have been found in men with advanced prostate cancer.
Hormone therapy is often used to treat prostate cancer that has spread to other parts of the body, but many patients develop resistance to hormone therapy, causing their disease to become more aggressive and potentially more deadly.
Patient Care Lung Cancer Prostate Cancer Melanoma Immunotherapy
To understand why Beau Gill built a mental cupboard for Jeff and Spike, first you must travel back with him to the small town of Catemaco in Mexico’s state of Veracruz.
Research Patient Care Prostate Cancer Clinical Trials
Carlos J. Castro transferred his care to Elizabeth Kessler, MD, University of Colorado Cancer Center member, after learning about a clinical trial that gave him a new treatment option for his stage 4 prostate cancer.
The diagnosis came as a shock. Although, looking back, Bill Mordecai says it shouldn’t have been.
Two members of the University of Colorado Cancer Center have received prestigious Idea Awards from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program (PRCRP).
New research from CU Cancer Center member Scott Cramer, PhD, and his colleagues could help in the treatment of men with certain aggressive types of prostate cancer.
Patient Care Philanthropy Prostate Cancer Magazine
Ashton Villars has always been a problem solver. As a competitive athlete in basketball, waterskiing, and tennis and an actual rocket scientist, Villars has tackled every challenge in life head on — including his prostate cancer diagnosis. Now, he’s bringing that same problem-solving spirit to supporting cancer research.
Research Prostate Cancer Bone Cancer
When prostate cancer spreads, it most often spreads to bone. And while the 5-year survival rate for prostate cancer that has not spread is nearly 100 percent, once the disease reaches bone, the 5-year survival rate is only 29 percent. Now a University of Colorado Cancer Center study published in the Journal for Immunotherapy of Cancer suggests a new approach, or, possibly two new approaches against these bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful against primary prostate cancers, the study suggests that both these approaches may be effective against the bone metastases that grow from primary prostate cancers, and, in fact, the type of bone metastasis may dictate which targeted therapies and immunotherapies work best.
Since the 1940’s, blocking the body’s production of androgen has been the only systemic therapy against prostate cancer. Today, while we’ve gotten better at targeting androgen signaling, treatments targeting the genetic causes of prostate cancer have lagged behind those for other forms of the disease.
Research Honors Prostate Cancer
The National Cancer Institute (NCI) is set up to fund individual projects in fields like genomics, computational biology, and pathology. Now researchers at University of Colorado Cancer Center are taking advantage of an innovative new program in cancer systems biology to combine the three research areas, earning a prestigious “U01” grant to study the complex genetic drivers of aggressive prostate cancer. By combining the tools of pathology, computational modeling and genomics, the project hopes to discover and test therapeutic interventions for three molecularly distinct types of prostate cancer.
“Prostate cancer is defined by its pathology – you take a biopsy, give it to a pathologist, and they score it, for example they will characterize it as ‘pathological stage 3 disease.’ What we want to do is to understand how genetics contributes to driving aggressive pathology. By understanding what pathways and processes are dysregulated by distinct genetic alterations, we can start to explore therapeutic options to match the genetic alterations,” says James Costello, PhD, CU Cancer Center investigator and assistant professor in the Department of Pharmacology at the CU School of Medicine.
In cancers like melanoma, there tends to be a single genetic driver.
“You have mutations in oncogenes such as BRAF or RAS that drives disease,” says Scott Cramer, PhD, investigator at the CU Cancer Center and professor in the CU School of Medicine Department of Pharmacology. “But in prostate, it’s tricky. Prostate cancer tends to be driven by the loss of tumor-suppressor genes – for example, you lose TP53 and the tumor can grow. In prostate, we find that aggressive disease is often associated with loss of multiple tumor suppressors.”
The field of cancer research is getting better and better at turning off oncogenes that cause cancer. However, the field is far less adept at therapeutically targeting cancers where good genes are lost. This means that in prostate cancer and other cancers created by loss of tumor suppressors, treatment isn’t as simple as switching these lost genes back on. Instead, this project hopes to discover what else happens in prostate cancers with loss of these tumor suppressor genes – possibly, in this tangled network of cause-and-effect, turning off a tumor suppressor like TP53 may turn on another gene that aids cancer growth. And if that’s the case, Costello, Cramer, and colleagues would have a target they could do something about – a target gene they could turn off.
Likewise, “In prostate, you get big deletions in chromosomes – there are multiple genes in there and we need to know which ones are the causal drivers of aggressive disease,” Cramer says.
In other words, deleted along with these known tumor-suppressor genes like TP53, may be the loss of many other genes. Some of these losses are unimportant – only about 1.2 percent of our genome is actually manufactured into proteins. But some losses may be additional drivers of cancer.
To discover these genetic drivers of prostate cancer, Costello and Cramer will turn off various combinations of genes in mouse models of the disease to see which combinations grow into aggressive cancers. Then the team will look inside these models of aggressive cancer to see which genetic pathways are affected.
“We end up with the genetically altered cells that drive the disease, which allows us to ask what is the most likely therapeutic target? Then we can treat mouse models with drugs and see if it’s successful,” Costello says. If these studies are promising the next step may be clinical trials in men with this aggressive form of prostate cancer.
Until recently, the project would have struggled to find funding.
“When you submit a grant, it gets evaluated by a ‘study section,’” says Cramer. “Most study sections are very focused – you submit this project to a pathology study section and they might not get the computational modeling that is used to help make sense of genome-wide measurements to identify therapeutic targets. But if you submit the grant to a computational modeling study section, they don’t get the pathology side and tend to score it poorly. The balance is tricky.”
With only 8 percent of cancer research project grant applications earning funding, even perceived weakness or misinterpretations by a reviewer in the study section can be fatal.
“The National Institutes of Health recognized there were research areas they wanted to fund that weren’t getting funded in standard study sections, so they developed the Cancer Systems Biology Consortium, for which the U01 is one mechanism to foster collaborations like this,” Costello says.
Despite decades of effort, no one set of tools has been able to point to the genes driving prostate cancer. Now with three sets of tools – genomics, computational modeling, and pathology – Cramer, Costello and CU Cancer Center colleagues hope to finally pinpoint the causes of aggressive prostate cancers. Knowing the cause is an important step toward finding a cure.
For most people finding out that they have prostate cancer multiple times in the span of just a few years seem like a cruel joke. But Jonathan Ormes is not most people. After being told for the third time that he had the disease he decided to take a chance on a University of Colorado Cancer Center study drug that, so far, is controlling his cancer. Ormes is not letting prostate cancer slow him down. In fact, he is using his experience to create poetry.
Research Prostate Cancer Cancer
A University of Colorado Cancer Center study published ahead of print in the journal Brachytherapy shows that intermediate risk prostate cancer patients experience modest benefit from the addition of external beam radiation therapy (EBRT) to brachytherapy. The study is based on the results of 10,571 patients, of which 3,148 received brachytherapy plus EBRT and 7,423 received brachytherapy alone. Overall survival rates were 91.4 percent versus 90.2 percent at five-year follow up, and 85.7 percent versus 82.9 percent at seven-year follow up.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Greg Glasgow
